Patients with triple negative breast cancer had improved event-free survival when carboplatin (but not the PARP inhibitor veliparib) was added to standard neoadjuvant chemotherapy.
Medscape Medical News
BrighTNess Follow-Up Data Shed Light on TNBC Therapy
